ING Groep NV Purchases 48,231 Shares of Stryker Co. (NYSE:SYK)

ING Groep NV grew its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 62.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 124,854 shares of the medical technology company's stock after acquiring an additional 48,231 shares during the period. ING Groep NV's holdings in Stryker were worth $45,105,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Koshinski Asset Management Inc. acquired a new stake in Stryker during the 1st quarter worth about $795,000. Wealth Enhancement Advisory Services LLC increased its position in Stryker by 78.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company's stock valued at $45,260,000 after buying an additional 58,673 shares in the last quarter. M&G Plc bought a new stake in Stryker in the 1st quarter valued at about $11,534,000. OFI Invest Asset Management increased its position in Stryker by 3,210.9% in the 2nd quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company's stock valued at $1,062,000 after buying an additional 3,243 shares in the last quarter. Finally, Tidal Investments LLC increased its position in Stryker by 14.2% in the 1st quarter. Tidal Investments LLC now owns 13,558 shares of the medical technology company's stock valued at $4,853,000 after buying an additional 1,681 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of NYSE SYK traded down $5.06 during midday trading on Thursday, reaching $383.28. The company's stock had a trading volume of 1,763,435 shares, compared to its average volume of 1,259,397. Stryker Co. has a 12-month low of $282.35 and a 12-month high of $392.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm has a 50 day moving average price of $362.94 and a 200-day moving average price of $346.72. The stock has a market capitalization of $146.11 billion, a P/E ratio of 41.62, a PEG ratio of 2.92 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter in the prior year, the business earned $2.46 earnings per share. Stryker's revenue for the quarter was up 11.9% on a year-over-year basis. As a group, equities analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 600 shares of the business's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now owns 9,069 shares of the company's stock, valued at $3,219,495. The trade was a 6.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP M Kathryn Fink sold 7,347 shares of the business's stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares in the company, valued at $3,685,213.16. The trade was a 42.25 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,381 shares of company stock worth $24,825,275. Insiders own 5.90% of the company's stock.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of research analyst reports. Robert W. Baird boosted their target price on Stryker from $378.00 to $405.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. Stifel Nicolaus decreased their target price on Stryker from $375.00 to $365.00 and set a "buy" rating for the company in a research report on Wednesday, July 31st. Needham & Company LLC boosted their target price on Stryker from $393.00 to $409.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Truist Financial boosted their target price on Stryker from $370.00 to $380.00 and gave the company a "hold" rating in a research report on Wednesday, October 30th. Finally, Barclays boosted their price objective on Stryker from $402.00 to $418.00 and gave the stock an "overweight" rating in a report on Thursday, October 31st. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $393.65.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.